Native Meta creative and exact outbound link observed October 22, 2026. Redirects were followed to the captured public destination. Advertiser claims are source material; activity does not establish performance. No personal, health or payment details were entered.

A treatment offer develops through customer stories, product education, the care process and a clear purchase entry. Compare the creative with the destination and explore the other ads sharing this route.
Selected for its design and offer structure. Ad performance isn’t available in this collection.
The image does the storytelling: a loose, cover-up style dress hanging alone says a lot about the year-ago version of the reader without showing a body at all. The headline builds a before and after into one sentence, with the second half switched to a lighter purple so the shift is visible. The single button and the LegitScript badge keep the frame uncluttered, which suits the reflective tone.
This is the one Brello static in the set without a price or inclusions in the image, so the viewer gets an emotional nudge with nothing concrete to weigh. The headline also hedges with “maybe”, and it's a summer message in an ad that started running on October 20, 2026, when the moment it describes is months away. Add the price and two inclusions under the button, and write a seasonal version for the months it actually runs (holiday photos, a winter wedding).
The garment stands in for the reader's past choices without showing a person.
It builds a before and after into one sentence, with the turn set in a lighter color.
One clear action and one proof seal keep the reflective frame uncluttered.
The caption carries the offer details the image leaves out.
The image shows no price; the headline below it offers Tirzepatide at $166/month (if approved).
The ad sends people to tirzepatidewoo.brellohealth.com, a dedicated Tirzepatide offer page rather than the homepage or a quiz, and it's one of 18 Brello ads in the library that point there. Because the ad itself never states a price, the page does the selling: the hero introduces Compounded Tirzepatide at $166 a month with the $499 three-month plan and a $749 anchor. That's a sharp turn from a reflective summer-wardrobe ad to a checkout box. The customer stories section carries a review about dropping clothing sizes, which is the closest echo of the dress, and placing a review like that near the hero (attributed, with results-may-vary language as the page uses elsewhere) would connect the two.
Brello's dedicated Tirzepatide offer page opens on a $166 a month special with the three-month plan box, then moves through reviews, treatment education, a four-step care path, inclusions and FAQs. It's where 18 Brello ads in the library land, all static image ads, built on emotional moments, native-style text posts and offer or inclusion lists.
A price lock banner, the vial with a $166 badge, and a plan box with the $499 three-month plan, Trustpilot rating, transfer note and intake explanation, answering what it costs and what happens when you pay.
Trusted by 80,000+ members with a Trustpilot rating and review cards about community, customer service and members' own results, answering whether people like you have done this.
A deeper look inside Tirzepatide, with a short explanation, a list of what studies examine, footnoted sources and a results-may-vary note, answering what the medication is.
A straightforward path to care in four photo steps (select your plan, provider review, ships to your door, ongoing support), answering how the process works.
What makes Brello different, with six inclusions beside a photo and a Take the First Step button, answering what you get beyond the medication.
Six questions on approval, refunds, timelines and replacements, then the study references, disclaimers and plan terms, answering the last practical doubts.
Read the full breakdown of this page
One of 22 Brello Health ads in the Fluid Inspiration Library, captured from the Meta Ad Library on Oct 22, 2026. We record that an ad ran publicly, not how it performed.